Search research articles
Contact Us
Filters
Showing results (201-210 of 212) with videos related to
Page
of 22
Sort By:
Hematological Oncology
|
May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials
Enrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
Blood Cancer Journal
|
December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.
Hemasphere
|
January 24, 2025
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
Sonia Morè, Irene Federici, Alessandra Bossi, et al.
American Journal of Hematology
|
March 10, 2016
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
Artur Jurczyszyn, Norbert Grzasko, Alessandro Gozzetti, et al.
Blood
|
April 14, 2026
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant
Clive S Zent, Enrico Tiacci, Robert J Kreitman, et al.
Haematologica
|
June 26, 2025
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
Anna Maria Frustaci, Andrea Galitzia, Mariano Lucignano, et al.
Haematologica
|
August 5, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
Haematologica
|
March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology
|
March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
Haematologica
|
November 28, 2024
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 212) with videos related to
Sort By:
Page
of 22
Hematological Oncology
|
May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials
Enrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
Blood Cancer Journal
|
December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.
Hemasphere
|
January 24, 2025
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
Sonia Morè, Irene Federici, Alessandra Bossi, et al.
American Journal of Hematology
|
March 10, 2016
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
Artur Jurczyszyn, Norbert Grzasko, Alessandro Gozzetti, et al.
Blood
|
April 14, 2026
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant
Clive S Zent, Enrico Tiacci, Robert J Kreitman, et al.
Haematologica
|
June 26, 2025
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
Anna Maria Frustaci, Andrea Galitzia, Mariano Lucignano, et al.
Haematologica
|
August 5, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
Haematologica
|
March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology
|
March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
Haematologica
|
November 28, 2024
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Page
of 22